Valeant’s Pursuit of Allergan: Go Big or Go Home
Valeant’s Pursuit of Allergan: Go Big or Go Home Motley Fool
View ArticleAllergan criticises performance of Valeant's recent acquisitions
Allergan criticises performance of Valeant's recent acquisitions First Word Pharma
View ArticleAllergan investors want up to $200 per share from Valeant
Allergan investors want up to $200 per share from Valeant Fierce Pharma
View ArticleNestle boosts skincare business with $1.4 bln Valeant deal
Nestle boosts skincare business with $1.4 bln Valeant deal Yahoo/Reuters
View ArticleValeant raises proposal for Allergan by $10.00 per share to $58.30 per share
Valeant raises proposal for Allergan by $10.00 per share to $58.30 per share The Fly on the Wall
View ArticleValeant ups the ante for Allergan instead of waiting for rejection
Valeant ups the ante for Allergan instead of waiting for rejection Marketwatch
View ArticleValeant, Pershing prepare to go hostile in Allergan bid
Valeant, Pershing prepare to go hostile in Allergan bid Yahoo/Reuters
View ArticleIs Valeant’s Big Offer for Allergan Big Enough?
Is Valeant’s Big Offer for Allergan Big Enough? Motley Fool
View ArticleFDA approves Valeant's toenail fungus treatment Jublia, drugmaker plans 3rd...
FDA approves Valeant's toenail fungus treatment Jublia, drugmaker plans 3rd quarter launch Yahoo/AP
View ArticleAckman says Allergan holders back takeover at $180
Ackman says Allergan holders back takeover at $180 Reuters
View ArticleAckman says followed the rules with Allergan investment
Ackman says followed the rules with Allergan investment Reuters
View ArticleAllergan Board Rejects Valeant’s Latest $54 Billion Bid
Allergan Board Rejects Valeant’s Latest $54 Billion Bid Bloomberg
View ArticleValeant plans hostile bid after Allergan board unanimously rebuffs latest...
Valeant plans hostile bid after Allergan board unanimously rebuffs latest acquisition offer Yahoo/AP
View ArticleThe Valeant Strategy: A Sustainable Model or a Shell Game?
The Valeant Strategy: A Sustainable Model or a Shell Game? WSJ Online
View ArticleVALEANT: How A Canadian Pharmaceutical Company Could Destroy The Industry As...
VALEANT: How A Canadian Pharmaceutical Company Could Destroy The Industry As We Know It Yahoo/Business Insider
View ArticleValeant Pharma's Arguments About Drug Research Are Misleading And Wrong
Valeant Pharma's Arguments About Drug Research Are Misleading And Wrong Forbes
View ArticleAllergan-Valeant Deal Gets Pershing Poison Pill Warning
Allergan-Valeant Deal Gets Pershing Poison Pill Warning Bloomberg
View ArticleValeant Headlines Puncture Strategy as Stock Drops: Opening Line
Valeant Headlines Puncture Strategy as Stock Drops: Opening Line Bloomberg
View ArticleAllergan Quotes Morgan Stanley to Attack Valeant, a Morgan Stanley Client
Allergan Quotes Morgan Stanley to Attack Valeant, a Morgan Stanley Client WSJ Online
View ArticleValeant Readies Hostile Exchange Offer for Allergan
Valeant Readies Hostile Exchange Offer for Allergan TheStreet.com
View Article